14. The method according to claim 9, wherein [the] at least one anti-LT-β-R monoclonal antibody [ies are] is CBE11 and at least one anti- LT-β-R monoclonal antibody is BHA10.

15. The method according to claim 9, wherein [the] at least one anti-LT-β-R monoclonal antibody [ies are] is CBE11 and at least one anti- LT-β-R monoclonal antibody is CDH10.

16. The method according to claim 9, wherein [the] at least one anti-LT-β-R monoclonal antibody [ies are] is AGH1 and at least one anti- LT-β-R monoclonal antibody is CDH10.

depends from cancel

17. The method according to any one of claims 6-16, [wherein one LT-β-R activating agent is] further comprising IFN-γ.

38. A pharmaceutical composition comprising a therapeutically effective amount of at least two LT-β-R activating agents, and a pharmaceutically acceptable carrier [The pharmaceutical composition according to claim 37], wherein at least one LT-β-R activating agent comprises an anti- LT-β-R antibody.

46. The pharmaceutical composition according to claim 41, wherein at least one [the] anti- LT-β-R monoclonal antibody[ies are] is CBE11 and at least one anti- LT-β-R monoclonal antibody is BHA10.

47. The pharmaceutical composition according to claim 41, wherein at least one [the] anti- LT-β-R monoclonal antibody[ies are] is CBE11 and at least one anti- LT-β-R monoclonal antibody is CDH10.

48. The pharmaceutical composition according to claim 41, wherein at least one [the] anti- LT-β-R monoclonal antibody[ies are] is AGH1 and at least one anti- LT-β-R monoclonal antibody is CDH10.

49. The pharmaceutical composition according to any one of the claims 41-48 further comprising IFN-γ [as one of the LT-β-R activating agents].

Please add the following new claims to the application.

61. The method according to claim 7, wherein the anti- LT-β-R antibody has the same epitope specificity as an antibody produced by cell line CB.E11.1, ATCC accession number HB11793.

62. The method according to claim 7, wherein the anti- LT-β-R antibody has the same epitope specificity as an antibody produced by cell line BH.A10, ATCC accession number HB11795.

63. The method according to claim 9, wherein at least one anti- LT-β-R antibody has the same epitope specificity as an antibody produced by cell line CB.E11.1, ATCC accession number HB11793

64. The method according to claim 9, wherein at least one anti- LT-β-R antibody has the same epitope specificity as an antibody produced by cell line BH.A10, ATCC accession number HB11795.

65. The method according to claim 64, further comprising at least one anti- LT-β-R antibody having the same epitope specificity as an antibody produced by cell line CB.E11.1, ATCC accession number HB11793.

66. The pharmaceutical composition according to claim 38, wherein the anti- LT-β-R antibody has the same epitope specificity as an antibody produced by cell line CB.E11.1, ATCC accession number HB11793.

67. The pharmaceutical composition according to claim 38, wherein the anti- LT-β-R antibody has the same epitope specificity as an antibody produced by cell line BH.A10, ATCC accession number HB11795.

68. The pharmaceutical composition according to claim 46, wherein at least one anti-LT-β-R antibody has the same epitope specificity as an antibody produced by cell line CB.E11.1, ATCC accession number HB11793.

69. The pharmaceutical composition according to claim 46, wherein at least one anti-LT-β-R antibody has the same epitope specificity as an antibody produced by cell line BH.A10, ATCC accession number HB11795.

70. The pharmaceutical composition according to claim 69, further comprising at least one anti- LT-β-R antibody having the same epitope specificity as an antibody produced by cell line CB.E11.1, ATCC accession number HB11793.

REMARKS

The instant application is a divisional of U.S.S.N. 08/875,560 ('560). In reply to the election requirement mailed October 14, 1999 in the '560 case Applicants elect prosecution of the method claims, species XI and XII (claims 7-17) and composition claims, species III and IV (claims 38-49) which are directed at compositions of at least two LT-β-R activating agents for treating neoplasia where at least one anti-LT-β-R activating agent is a LT-β-R antibody.

Upon entry of the present amendment, claims 7-17 and 38-49 will remain pending in the above-identified application as well as new claims 61-70.